Search Results - "Barsotti, Giulia"

The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma by Procaccio, Letizia, Merz, Valeria, Fasano, Morena, Vaccaro, Vanja, Giommoni, Elisa, Pretta, Andrea, Noventa, Silvia, Satolli, Maria Antonietta, Giordano, Guido, Zichi, Clizia, Pinto, Carmine, Zecchetto, Camilla, Barsotti, Giulia, De Vita, Ferdinando, Milella, Michele, Antonuzzo, Lorenzo, Scartozzi, Mario, Zaniboni, Alberto, Spadi, Rosella, Casalino, Simona, Bergamo, Francesca, De Toni, Chiara, Melisi, Davide, Lonardi, Sara

“…Background The NAPOLI‐I trial showed better outcome of nanoliposomal irinotecan (nal‐IRI) plus 5‐fluorouracil/leucovorin (5‐FU/LV) compared to 5‐FU/LV in…”
Get full text

Real-world impact of olaparib use in patients (pts) with advanced pancreatic cancer (PC) harboring germline BRCA 1/2 (g BRCA ) mutations by Milella, Michele, Orsi, Giulia, Di Marco, Mariacristina, Salvatore, Lisa, Procaccio, Letizia, Noventa, Silvia, Bozzarelli, Silvia, Garajova, Ingrid, Vasile, Enrico, Giordano, Guido, Macchini, Marina, Cavaliere, Alessandro, Gaule, Marina, Barsotti, Giulia, Palloni, Andrea, Tortora, Giampaolo, Sperduti, Isabella, Reni, Michele

“…e16278 Background: g BRCA mutations are found in approximately 8% of Italian PC pts screened within 3 months from diagnosis. g BRCA PC pts display enhanced…”
Get full text

Real-world performance and clinical outcome of comprehensive genomic profiling of gastrointestinal tumors: High-volume, single-center experience by Ricagno, Gianmarco, Angerilli, Valentina, Maddalena, Giulia, De Toni, Chiara, Gasparello, Jessica, Barsotti, Giulia, Mattiuzzo, Elena, Ceccon, Carlotta, Montagna, Aldo, Sabbadin, Marianna, Pittarello, Chiara, Nappo, Floriana, Cerantola, Riccardo, Pante, Francesca, Procaccio, Letizia, Rizzato, Mario Domenico, De Rosa, Antonio, Fassan, Matteo, Bergamo, Francesca, Lonardi, Sara

“…727 Background: In order to identify targetable mutations, the Comprehensive Genomic Profiling (CGP) is an important tool. Technologies like extensive genomic…”
Get full text

Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV by Pietrantonio, Filippo, Bergamo, Francesca, Rossini, Daniele, Ghelardi, Filippo, De Grandis, Maria Caterina, Germani, Marco Maria, Barsotti, Giulia, Formica, Vincenzo, Frassineti, Giovanni Luca, Boscolo, Giorgia, Cinieri, Saverio, Di Donato, Samantha, Antonuzzo, Lorenzo, Antoniotti, Carlotta, Ambrosini, Margherita, Piva, Vittoria Matilde, Nichetti, Federico, Fassan, Matteo, Cremolini, Chiara, Lonardi, Sara

“…BACKGROUNDUpfront anti-EGFR therapy represents the standard of care for patients with left-sided, MSS/pMMR, RAS and BRAF wild-type mCRC. Molecular…”
Get full text

The oncological multidimensional prognostic index is a promising decision-making tool: A real-world analysis in older patients with metastatic colorectal cancer by Procaccio, Letizia, Bergamo, Francesca, Gatti, Maura, Chiusole, Benedetta, Tierno, Giuseppina, Bergo, Eleonora, Daniel, Francesca, Nappo, Floriana, Maddalena, Giulia, Rasola, Cosimo, Barsotti, Giulia, De Grandis, Maria C., Piva, Vittoria M., Rizzato, Mario D., Sergi, Giuseppe, Brunello, Antonella, Zagonel, Vittorina, Lonardi, Sara

“…Approximately 50% of colorectal cancers occur in older patients. International societies recommend geriatric tools to optimise treatment of older patients…”
Get full text

Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study by Nappo, Floriana, Fornaro, Lorenzo, Pompella, Luca, Catanese, Silvia, Lavacchi, Daniele, Spallanzani, Andrea, Cappetta, Alessandro, Puzzoni, Marco, Murgioni, Sabina, Barsotti, Giulia, Tirino, Giuseppe, Pellino, Antonio, Vivaldi, Caterina, Strippoli, Antonia, Aprile, Giuseppe, Di Donato, Samantha, Mazza, Elena, Prisciandaro, Michele, Antonuzzo, Lorenzo, Zagonel, Vittorina, Cascinu, Stefano, De Vita, Ferdinando, Lonardi, Sara

“…Background FLOT regimen is the standard perioperative treatment in Western countries for patients with locally advanced gastric (GC) or gastroesophageal…”
Get full text

Understanding resistance in V600E BRAF advanced colon cancer treated with BRAF inhibitors plus anti-EGFR antibodies +/- MEK inhibitors: The URBAN study by Bergamo, Francesca, Munari, Giada, Cerma, Krisida, Ceccon, Carlotta, Intini, Rossana, Borga, Chiara, Cerantola, Riccardo, Piva, Vittoria Matilde, Angerilli, Valentina, Prete, Alessandra Anna Anna, Montagna, Aldo, Rizzato, Mario Domenico, Sabbadin, Marianna, Barsotti, Giulia, De Toni, Chiara, Procaccio, Letizia, Soldà, Caterina, Dei Tos, Angelo Paolo, Lonardi, Sara, Fassan, Matteo

“…3587 Background: The combination of BRAF inhibitors (BRAFi) plus anti-EGFR antibodies is a new standard of care in V600E BRAF mutated (mut) metastatic…”
Get full text

Immunotherapy in RAS mutant mCRC: Could CTLA-4 blockade increase the efficacy of anti PD-1 agents? Preliminary clinical results of the NERDY study by Prete, Alessandra Anna Anna, Intini, Rossana, Piva, Vittoria Matilde, Angerilli, Valentina, Daniel, Francesca, Barsotti, Giulia, De Grandis, Maria Caterina, Cerma, Krisida, Munari, Giada, Ricagno, Gianmarco, Montagna, Aldo, De Toni, Chiara, Rossi, Silvia, Cerantola, Riccardo, Rasola, Cosimo, Schiavi, Francesca, Fassan, Matteo, Bergamo, Francesca, Zagonel, Vittorina, Lonardi, Sara

“…218 Background: Immune checkpoint inhibitors (ICI) showed high efficacy in both first and subsequent lines in metastatic colorectal cancer with mismatch repair…”
Get full text

HER2 expression and extensive molecular characterization of resected brain metastases from colorectal cancer: The HEROES study by Prete, Alessandra, Bergamo, Francesca, Intini, Rossana, Murgioni, Sabina, De Grandis, Maria Caterina, Piva, Vittoria Matilde, Barsotti, Giulia, Daniel, Francesca, Rizzato, Mario Domenico, Salmaso, Roberta, Angerilli, Valentina, Munari, Giada, Baro, Valentina, Chioffi, Franco, Vettore, Valentina, Carcea, Elena, Montagna, Aldo, Zagonel, Vittorina, Fassan, Matteo, Lonardi, Sara

“…2025 Background: Brain metastases (BM) from primary colorectal cancer (prCRC) are rare (1-3%); few is known about CRC BM predictive factors, prognosticators…”
Get full text

A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study by Procaccio, Letizia, Bergamo, Francesca, Daniel, Francesca, Rasola, Cosimo, Munari, Giada, Biason, Paola, Crucitta, Stefania, Barsotti, Giulia, Zanella, Giulia, Angerilli, Valentina, Magro, Cristina, Paccagnella, Silvia, Di Antonio, Veronica, Loupakis, Fotios, Danesi, Romano, Zagonel, Vittorina, Del Re, Marzia, Lonardi, Sara, Fassan, Matteo

“…Background: First-line decision making is the key to the successful care of mCRC patients and RAS/BRAF status is crucial to select the best targeted agent. In…”
Get full text